



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1635
JFW

Applicant(s): Li et al. Group Art Unit: 1635
Serial No.: 10/038,984 Examiner: : K. Lacourciere
Filed: 4 January 2002 Docket No.: 275.00030102
Confirmation No.: 9705
Title: COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION GENE
EXPRESSION USING DOUBLE STRANDED RNA

Assistant Commissioner for Patents
Mail Stop Amendments
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):


- ☒ Small entity status is entitled to be asserted in the above-identified application.
☒ An itemized return postcard.
☒ A Supplemental Information Disclosure Statement (2 pgs); copies of 1 applications; 1449 forms (1 pg);
and copies of 2 documents cited on the 1449 forms.
Other: _____

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$43 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$145 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 18th day of May, 2004.

MUETING, RAASCH & GEBHARDT, P.A.
Customer Number: 26813

By: 
Name: Victoria A. Sandberg
Reg. No.: 41,287
Direct Dial: 612-305-1226
Facsimile: 612-305-1228



PATENT
Docket No. 275.00030102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Li et al.)	Group Art Unit:	1635
)		
Serial No.:	10/038,984)	Examiner:	K. Lacourciere
Confirmation No.:	9705)		
)		
Filed:	January 4, 2002)		
)		
For:	COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION USING DOUBLE STRANDED RNA			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendments

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

Applicants also wish to bring the Examiner's attention to the following pending U.S. Applications, as well as any documents, Office Actions that may include rejections of similar claims, and any provisional U.S. patent applications referenced in the pending U.S.



Supplemental Information Disclosure Statement

Page 2 of 2

Applicant(s): Li et al.

Serial No.: 10/038,984

Confirmation No.: 9705

Filed: 4 January 2002

For: COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION GENE EXPRESSION USING DOUBLE STRANDED RNA


applications or in their file wrappers. A copy of each of the below-listed pending U.S. Patent Applications is provided herewith.

List of Pending Non-Published U.S. Patent Applications

Applicant(s)	Application Number	Filing Date	Serial No. of Provisional Application to which listed Application claims priority
Li et al.	10/772,661	February 5, 2004	60/117,635 and 60/175,440

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.


Respectfully submitted for
Li et al.


CERTIFICATE UNDER 37 C.F.R. 1.8:
The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>18th</u> day of <u>May</u> , 2004.
 Name: <u>VICTORIA A. SANDBERG</u>

By
Mueiting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813

May 18, 2004
Date

VAS/sjt

By: 
Victoria A. Sandberg
Reg. No. 41,287
Direct Dial (612)305-1226



INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.0003 0102	Serial No.: 10/038,984
	Applicant(s): LI et al.	Confirmation No.: 9705
	Application Filing Date:	Group: 1635
	Information Disclosure Statement mailed: May <u>18</u> , 2004	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		None					

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		None						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copies Enclosed	Document Description
	X	Katze, "Regulation of the Interferon-Induced PKR: can viruses cope?". Trends in Microbiology. Vol. 3, No. 2, February 1995, pp. 75-78
	X	Proud, "PKR: a new name and new roles". Trends in Biochemical Sciences. June 1995, Volume 20, No. 6, pp. 241-246

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	